Hana ʻo AASraw i nā pauka NMN a me NRC i ka nui!

Lenvatinib

 

  1. Mōʻaukala o Lenvatinib
  2. He aha ʻo Lenvatinib?
  3. ʻO Lenvatinib Mekanism o ka hana
  4. He aha ka mea e hoʻohana ʻia ai ʻo Lenvatinib?
  5. He aha nā hopena e ʻike ai paha wau ke hoʻohana ʻoe iā Lenvatinib?
  6. Nā Hopena Haukino Lenvatinib (ʻAe ʻA FDA)
  7. Ma hea wau e mālama ai iā Lenvatinib?
  8. Nā lāʻau e pili ana: Lenvatinib Mesylate (CAS: 857890-39-2)
  9. Ma hea e hiki ai iā mākou ke kūʻai iā Lenvatinib ma ka pūnaewele?

 

Mōʻaukala O Lenvatinib

Ua hana ʻia kahi mahele hoʻokolohua hoʻokolohua ma nā maʻi maʻi ʻaʻai i 2006. [8] Ua hoʻomaka ʻia kahi hoʻokolohua ʻekolu e mālama ana i nā mea maʻi ʻaʻai thyroid i Malaki 2011.

Ua hāʻawi ʻia ʻo Lenvatinib i ke kūlana lāʻau makua ʻole no ka mālama ʻana i nā ʻano ʻano like ʻole o ka maʻi ʻaʻai like ʻole i pane i ka radioiodine ma US a me Iapana ma 2012 a me ʻEulopa i ka 2013.

I Pepeluali 2015, ua ʻae ka US FDA iā lenvatinib no ka hoʻomaʻamaʻa ʻana i ka holomua, radioiodine refractory ʻokoʻa ka maʻi ʻaʻai thyroid. I Mei 2015, ua ʻae ʻo European Medicines Agency (EMA) i ka lāʻau no ka hōʻike like.

I ka Mei 2016, ua ʻae ʻo FDA iā ia (me ka everolimus) no ka mālama ʻana i ka carcinoma cell renal holomua ma hope o kekahi anti-angiogenic therapy.

I ʻAukake 2018, ua ʻae ka FDA i ka lenvatinib no ka lālani mua o nā poʻe me ka maʻi hepococularular carcinoma (HCC).

 

He aha Lenvatinib?

Lenvatinib (CAS:417716-92-8) he receptor tyrosine kinase (RTK) mea kāohi i hana i nā hana kinase o nā kumu ulu ulu endothelial (VEGF) nā mea loaʻa ʻo VEGFR1 (FLT1), VEGFR2 (KDR), a me VEGFR3 (FLT4). Pākuʻi pū ʻo Lenvatinib i nā RTK ʻē aʻe i hoʻopili ʻia i ka angiogenesis pathogenic, ka ulu ʻana o ka tumo, a me ka holomua ʻana o ka maʻi ʻaʻai me ka hoʻohui ʻana i kā lākou mau hana cellular maʻamau, e like me ka loaʻa ʻana o ka fibroblast factor factor (FGF) iā FGFR1, 2, 3, a me 4; ka platelet i loaʻa i ka mea ulu ulu alpha (PDGFRα), KIT, a me RET. ʻO kēia mau receptor tyrosine kinases (RTKs) aia i loko o ka membrane pūnaewele kahi hana nui i ka hoʻoulu ʻana o nā ala transduction hōʻailona e pili ana i ka hoʻoponopono maʻamau o nā hana kelepona, e like me ka hoʻonui ʻana o ka cell, ka neʻe ʻana, apoptosis a me ka hoʻokaʻawale ʻana, a me ka angiogenesis pathogenic, lymphogenesis, ka ulu ʻana o ka tumo a me ka holomua ʻana o ka maʻi ʻaʻai. Ma kahi kikoʻī, ua ʻike ʻia ʻo VEGF ma ke ʻano he mea hoʻokele koʻikoʻi o nā angologogenic a me nā pathologic angiogenesis a me ka hoʻonui ʻia ʻana o ka VEGF e pili ana me kahi wānana maikaʻi ʻole i nā ʻano maʻi ʻaʻai.

Hōʻike ʻia ʻo Lenvatinib no ka mālama ʻana i nā mea maʻi me ka recurrent a metastatic kūloko paha, holomua, radioactive iodine (RAI) -refractory ʻokoʻa ka maʻi ʻaʻai thyroid. ʻO ka hapa nui o nā mea maʻi me ka maʻi ʻaʻai thyroid i kahi wānana maikaʻi loa me ka hoʻomaʻamaʻa (98% 5 makahiki o ke ola) e pili ana i ka ʻoki a me ka hormone therapy. Eia nō naʻe, no nā mea maʻi me ka RAI-refactory thyroid cancer, ua kaupalena ʻia nā koho lapaʻau ʻana a maikaʻi ʻole ka wānana, e alakaʻi ana i ka mea e hoʻomohala ai i nā mea i hoʻomākaukau ʻia e like me ka lenvatinib.

 

Lenvatinib Ka hana hana

ʻO Lenvatinib kahi receptor tyrosine kinase (RTK) mea kāohi ka mea e kāohi i nā hana kinase o nā kumu ulu ulu endothelial (VEGF) nā mea loaʻa ʻo VEGFR1 (FLT1), VEGFR2 (KDR), a me VEGFR3 (FLT4). Pākuʻi pū ʻo Lenvatinib i nā RTK ʻē aʻe i hoʻopili ʻia i ka angiogenesis pathogenic, ka ulu ʻana o ka tumo, a me ka holomua ʻana o ka maʻi ʻaʻa me kā lākou hana maʻamau maʻamau, e like me ka loaʻa ʻana o ka fibroblast factor factor (FGF) FGFR1, 2, 3, a me 4; ʻo ka platelet i loaʻa i ka mea ulu ulu alpha (PDGFRα), KIT, a me RET.

ʻO AASraw ka mea hana ʻoihana ʻo Lenvatinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

He aha Lenvatinib Hoʻohana ʻia no? 

Hoʻohana ʻia ʻo Lenvatinib e mālama i kekahi ʻano o thyroid maʻi ʻaʻai i hoʻi mai a i ʻole ua pāhola i nā ʻāpana ʻē aʻe o ke kino a ʻaʻole hiki ke mālama ʻia me ka iodine radioactive.

Hoʻohana pū ʻia ʻo Lenvatinib me everolimus (Afinitor, Zortress) e mālama ai i ka maʻi puʻuwai puʻuwai puʻupaʻa (RCC, kahi ʻano o ka maʻi ʻaʻai e hoʻomaka ai i ka puʻupaʻa) i ka poʻe i loaʻa mua i ka lāʻau me kekahi lāʻau chemotherapy.

Hoʻohana ʻia ʻo Lenvatinib e mālama maʻi kanesa hepatocellular (HCC; kahi ʻano maʻi ʻaʻai ate) ʻaʻole hiki ke mālama ʻia me ke ʻoki kino.

Hoʻohana pū ʻia ʻo Lenvatinib me pembrolizumab (Keytruda) e mālama ai i kekahi ʻano o Ka maʻi 'aʻai o ka endometrium (lining o ka uterus) i pālahalaha ʻia i nā ʻāpana ʻē aʻe o ke kino a i ʻole worsened i ka wā a ma hope paha o ka mālama ʻana me nā lāʻau chemotherapy a i ʻole hiki ʻole ke mālama ʻia me ke kahakaha a me ka radiation radiation.

❺ Aia ʻo Lenvatinib i kahi papa o nā lāʻau i kapa ʻia ʻo nā kinase inhibitors. Hana ia ma ke kāpae ʻana i ka hana o kahi protein pono ʻole e hōʻailona ai i nā hunaola maʻi ʻaʻai e hoʻonui. Kōkua kēia i ka hōʻoki ʻana i nā hunaola maʻi ʻaʻai.

 

Heaha Side Ehelehelena May I Nʻope When Hoʻohana ʻoe Lenvatinib?

Nā hopena ʻaoʻao āu e hōʻike ai i kāu kauka a i ʻole ʻoihana mālama ola i ka wā hiki loa.

▪ nā hopena āpau e like me ka ʻili o ka ʻili, ka huehue a i ka hives, ka pehu ʻana o ka maka, nā lehelehe, a me nā alelo

▪ pilikia hanu

▪ ʻeha o ka umauma a palpitations paha

▪ hoʻoluliluli

▪ maule a maule paha, hina

▪ ʻeha poʻo

▪ ke koko kiʻekiʻe

▪ ka hopu ʻana

▪ nā hōʻailona a me nā ʻōuli o ke kahe ʻana e like me ke koko a me ka ʻeleʻele, nā noho lōʻihi; mimi ʻulaʻula a ʻeleʻele-ʻeleʻele; kuha ana i ke koko a i ʻole mea ʻulaʻula e like me ke kahua kope; nā kiko ʻulaʻula ma ka ʻili; ʻeha a kolo paha mai ka maka, gum, a ihu paha

▪ nā hōʻailona a me nā ʻōuli o kahi loli weliweli o ka puʻuwai a i ʻole ka puʻuwai e like me ka ʻeha o ka umauma; ʻūpā; wikiwiki a i ʻole kōkō puʻuwai puʻuwai; palpitations; palupalu paha, hāwele; nā pilikia hanu

▪ nā hōʻailona a me nā ʻōuli o ka ʻehaʻeha e like me ka pilikia e hele i ka mimi a i ʻole ka hoʻololi ʻana i ka nui o ka mimi

▪ hōʻailona a me nā ʻōuli o ka hōʻeha o ke ake e like me ka melemele melemele a i ʻole ka mimi ʻeleʻele; ka manaʻo maʻi maʻamau a i ʻole nā ​​maʻi like flu; nā noho waihoʻoluʻu māmā; nele i ka makemake ʻole; nausea; ʻeha o ka ʻōpū o luna pono; nawaliwali a luhi paha; melemele o nā maka a i ʻole ʻili

▪ nā hōʻailona a me nā ʻōuli o ka potassium haʻahaʻa e like me ka ʻūpī ʻana i nā mākala a i ʻole ka ʻehaʻeha o nā mākala; ʻeha ka umauma; ʻūpā; maule a maule paha, hina; palpitations; nā pilikia hanu; a i ʻole ka wikiwiki, ka puʻuwai puʻuwai ʻole

▪ nā hōʻailona a me nā ʻōuli o ke kuʻi e like me ka hoʻololi o ka hihiʻo; huikau; pilikia i ka ʻōlelo ʻana a i ʻole ka hoʻomaopopo ʻana; ʻeha ke poʻo i ke poʻo; ʻōlohelohe ʻole a nawaliwali paha o ka maka, ka lima a me ka wāwae; pilikia hele wāwae; ʻūpā; nalo o ke kaulike a me ka hoʻohui ʻana

▪ ʻeha ka ʻōpū

▪ ka pehu ʻana o nā wāwae a i ʻole nā ​​kuʻekuʻe wāwae

▪ nāwaliwali a luhi paha

 

Nā hopena ʻaoʻao e koi ʻole ai i ka lāʻau olakino (e hōʻike i kāu kauka a i ʻole ʻoihana mālama ola inā hoʻomau lākou a pilikia paha).

▪ pāhoehoe

▪ ʻeha pū

▪ nalo o ka makemake ʻole

▪ ʻehaʻeha waha

▪ ʻeha ʻeha

▪ nausea, luaʻi

▪ hoʻēmi kino

ʻAʻole hiki i kēia papa inoa ke wehewehe i nā hopena ʻaoʻao āpau. Kāhea i kāu kauka no ka ʻōlelo aʻoaʻo olakino e pili ana i nā hopena. Hiki paha iā ʻoe ke hōʻike i nā hopena i FDA ma 1-800-FDA-1088.

 

Lenvatinib

 

Lenvatinib Nā Hopena Lapaʻau(ʻApono ʻo FDA)

ka ʻAe ʻia ka FDA o Lenvatinib i hoʻokumu ʻia ma ka multicenter, randomized, blind-blind, placebo-control trial i nā kumuhana 392 me ka iodine-refactory radioacte kūloko a metastatic paha. thyroid ʻo ka maʻi ʻaʻai a me nā hōʻike radiographic o ka holomua o ka maʻi ma waena o 12 mau mahina ma mua o ka randomization, hōʻoia e ka loiloi radiologic loiloi. Loaʻa nā kumuhana iā Lenvatinib 24 mg i kēlā me kēia lā (n = 261) a i ʻole placebo (n = 131) a hiki i ka holo ʻana o ka maʻi. Ua hōʻike nā hualoaʻa noiʻi Lenvatinib i nā mea i mālama ʻia ma waena o 18.3 mau mahina me ka ʻole o kā lākou maʻi e holo nei (ola holomua ʻole), hoʻohālikelike ʻia me ka median o 3.6 mau mahina no nā kumuhana i loaʻa kahi placebo. Hoʻohui ʻia, 65% o nā kumuhana i mālama ʻia me Lenvatinib i ʻike i ka hoʻēmi o ka nui tumo, i hoʻohālikelike ʻia me 2% o nā kumuhana i loaʻa kahi placebo.

ʻO AASraw ka mea hana ʻoihana ʻo Lenvatinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Ma hea wau e mālama ai iā Lenvatinib?

E mālama i ka hikiʻole o nā keiki.

Hale kūʻai ma waena o 20 a me 25 kekelē C (68 a me 77 kekelē F). Kiola i nā lāʻau i hoʻohana ʻole ʻia ma hope o ka lā palena pau.

MEA KAHAKAHA: ʻO kēia pepa kahi hōʻuluʻulu manaʻo. ʻAʻole paha e uhi ʻia i ka ʻike hiki. Inā he mau nīnau kāu e pili ana i kēia lāʻau, e kamaʻilio me kāu kauka, kauka lāʻau, a mea mālama ola.

 

Nā lāʻau lapaʻau e pili ana: Lenvatinib Mesylate (CAS: 857890-39-2)

ʻO Lenvatinib mesylate (CAS: 857890-39-2) kahi mea synthetic, waha e loaʻa ai ka mea kāohi o ka votype endothelial factor factor receptor 2 (VEGFR2, i ʻike ʻia ʻo KDR / FLK-1) tyrosine kinase me ka hiki i ka antineoplastic activity. Paukū ʻo E7080 i ka hoʻoulu ʻana o VEGFR2 e VEGF, i ka hopena o ka pāpā ʻana i ke ala lawe transduction hōʻailona VEGF, hoʻemi i ka neʻe ʻana o ka cell endothelial vascular a me ka hoʻonui ʻana, a me apoptosis cell endothelial vascular.

Lenvatinib mesylate he paʻakai methanesulfonate i loaʻa i ka hopena o ka lenvatinib me hoʻokahi molar like o ka methanesulfonic acid. ʻO kahi mea kāohi nui a me nā keiki makua ʻole i hoʻohana ʻia (e like me ka paʻakai mesylate) no ka mālama ʻana i nā ʻano ʻano like ʻole o ka maʻi ʻaʻa thyroid e pane ʻole i ka radioiodine. He kuleana kona ma ke ʻano he EC 2.7.10.1 (receptor protein-tyrosine kinase) mea kāohi, he fibroblast ulu mea loaʻa antagonist, kahi lāʻau makua ʻole, kahi vagon endothelial ulu mea ulu antagonist a me kahi mea antineoplastic. Loaʻa iā ia he lenvatinib (1+).

 

ʻAe ʻia ʻo Lenvatinib mesylate e hoʻohana hoʻokahi a i ʻole me nā lāʻau ʻē aʻe e mālama ai:

♦ Endometrial carcinoma e holomua a hele a maikaʻi loa ma hope o nā hoʻoponopono ʻē aʻe. Hoʻohana ʻia ia me ka pembrolizumab i nā mea maʻi ʻaʻohe microsatelit instability-high (MSI-H) a i ʻole mismatch hoʻoponopono hemahema (dMMR) a hiki ʻole ke mālama ʻia me ke kahakaha a me ka radiation radiation.

♦ Hepatocellular carcinoma (kahi ʻano maʻi ʻaʻai ate). Hoʻohana ʻia ia ma ke ʻano he lālani mua i nā maʻi i hiki ʻole ke lawe ʻia ko lākou maʻi e ke ʻoki.

♦ Ka maʻi puʻuwai ʻōhua (kahi ʻano maʻi ʻaʻai kolo) i holomua. Hoʻohana ʻia ia me everolimus i nā mea maʻi i loaʻa mua i ka angiogenesis inhibitor therapy.

ʻO ka maʻi ʻaʻai thyroid i kekahi mau maʻi me ka maʻi holomua, hoʻi hou, a metastatic paha e pane ʻole i ka mālama ʻana me ka iodine radioactive.

Ua ʻae ʻia kēia hoʻohana ma lalo o ka Polokalamu ʻApono ʻApono o FDA. Ma ke ʻano he ʻae, pono e hōʻike nā hōʻoia hoʻokolohua e hāʻawi i ka lenvatinib mesylate i kahi pōmaikaʻi olakino i kēia mau maʻi. Ke aʻo ʻia nei ʻo Lenvatinib mesylate i ka mālama ʻana i nā ʻano maʻi ʻē aʻe.

 

Ma hea e hiki ai iā mākou ke kūʻai Lenvatinib online no?

Nui a hewahewa nā mea hoʻolako / mea hana o ka lenvatinib pauka i ka mākeke, ke ʻike nei he mea nui ia no nā poʻe āpau e pono koke i kēia huahana. Ke hoʻoholo mākou e kūʻai i ka pauma lenvatinib i ka mākeke, pono mākou e aʻo hou e pili ana i ia mea, ʻike pehea e hoʻohana ai a me ia ʻano hana o ka hana, nā pilikia ke lawe mākou i ka pauma lenvatinib…. Eia hou, ʻo ke kumukūʻai a me ka maikaʻi e lilo i kā mākou hopohopo ma mua o ka kūʻai ʻana.

Ma hope o kā mākou nānā ʻana i nā ʻikepili mai ka mākeke, hoʻohālikelike ʻia i nā mea hoʻolako, nānā maikaʻi ʻo AASraw no nā poʻe e makemake e kūʻai i ka nui. pauma lenvatinib, kāohi ʻia kā lākou hana ma lalo o ke kūlana cGMP, hiki ke nānā i ke ʻano i kēlā me kēia manawa a hāʻawi paha lākou i nā hōʻike hoʻāʻo a pau ke kauoha ʻoe. No nā koina lenvatinib pauka / kumukūʻai, pono ia, i koʻu mau maka. Ma muli o ka loaʻa ʻana o nā kumukūʻai he nui mai nā mea hoʻolako like ʻole, hoʻohālikelike ʻia me ka maikaʻi, manaʻo wau ʻaʻole maikaʻi ʻole ka aasraw.
No nā kikoʻī hou aʻe, ʻoluʻolu e kamaʻilio me AASraw!

 

Reference

[1] H. Erdem, C. Gündogdu, a me S. Üipal, "Hoʻohui o E-cadherin, VEGF, ʻōlelo COX-2 i nā palena prognostic i ka papillary thyroid carcinoma," Experimental and Molecular Pathology, vol. 90, ʻaʻole. 3, pp. 312-317, 2011.

[2] M. Yagi, S. Kato, Y. Kobayashi et al., "Hoʻonohonoho koho ʻana o ka mea ulu ulu i loaʻa i ka platelet (PDGF) a me nā hanana cellular i hoʻopili ʻia e PDGF e kahi derivative quinoline," Experimental Cell Research, vol. 234, ʻaʻole. 2, pp. 285–292, 1997.

[3] P. Soares, J. Lima, A. Preto et al., "Ke hoʻololi nei i nā genetic i ka maikaʻi ʻole a me ka hoʻokae ʻole ʻia o ka thyroid carcinomas," I kēia manawa. ʻO Genomics, vol. 12, ʻaʻole. 8, pp. 609-617, 2011.

[4] MM Moura, BM Cavaco, V. Leite. ʻO RAS proto-oncogene i ka carroidoma thyroid medullary. Endocr Relat Cancer, 22 (5) (2015), pp. R235-R252.

[5] ʻO BR Haugen, SI Sherman Ke hele nei i nā mea maʻi me ka maʻi ʻaʻa thyroid like ʻole. Endocr Rev, 34 (3) (2013), pp. 439-455.

[6] M. Xing, D. Clark, H. Guan, et al. ʻO ka hoʻowalewale BRAF hoʻokolohua o ka hoʻokolohua biopsy aspiration pono-kele no ka stratification pilikia mua ma ka maʻi papillary thyroid. ʻO J Clin Oncol, 27 (18) (2009), pp. 2977-2982.

[7] SR Wedge, DJ Ogilvie, M. Dukes, et al. Hoʻopili ka ZD6474 i ka ulu ulu endothelial vascular signaling, angiogenesis, a me ka ulu ulu ʻana ma hope o ka hoʻoponopono waha. ʻO Cancer Res, 62 (16) (2002), pp. 4645-4655.

[8] SI Sherman, EEW Cohen, P. Schoffski, et al. Ka maikaʻi o ka cabozantinib (Cabo) i nā maʻi maʻi thyroid med Mull (MTC) me RAS a i ʻole nā ​​hoʻololi RET: Nā hopena mai kahi ʻāpana III haʻawina [abstract]. ʻO J Clin Oncol, 31 (15 Suppl.) (2013) abstr 6000.

[9] SI Sherman, LJ Wirth, JP Droz, et al. Motesanib diphosphate i ka holomua e hoʻokaʻawale i kou maʻi ʻaʻai maʻi ʻaʻai. N Engl J Med, 359 (1) (2008), pp. 31-42.

[10] K. Okamoto, K. Kodama, K. Takase, et al. ʻO nā hana Antitumor o ka multi-tyrosine kinase inhibitor lenvatinib (E7080) kūʻē i nā RET gen fusion-driven tumor models Cancer Lett, 340 (1) (2013), pp. 97-103.

[11] E. Cabanillas, M. Schlumberger, B. Jarzab, et al. ʻO kahi pae 2 hoʻokolohua o lenvatinib (E7080) i ka holomua, holomua, radioiodine-refactory, ʻokoʻa ka maʻi ʻaʻai thyroid: kahi hopena maʻi a me biomarker loiloi Cancer, 121 (16) ( 2015), pp. 2749-2756.

0 Likes
72 Views

E hiki no hoi i like

Comments ua paa.